ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
20 2월 2025 - 5:19PM
Business Wire
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, announces today that its
clinical development in sepsis has been selected as part of the
“i-Démo” call for projects under the France 2030 plan, operated by
Bpifrance on behalf of the French government.
After 6 months of examining ABIONYX Pharma’s CER-001 Sepsis
project, a panel of experts was able to validate and objectify the
quality of the project in its scientific, technological and
clinical aspects.
The CER-001 Sepsis project represents a strategic cornerstone
for ABIONYX Pharma, leveraging its unique expertise to use the only
recombinant apoA-I protein in the treatment of the most severe
inflammation in the human body.
The ABIONYX Pharma Sepsis project currently operates on two
strategic fronts:
- An integrated biomedicine approach: ABIONYX Pharma develops a
combined bioproduction/biotherapy approach secured by proprietary
patents until 2042 along the entire chain.
- An innovative clinical strategy: circulating apoA-I collapses
in situations of severe inflammation. Supplementation with
recombinant human apoA-I in these critical situations enables to
treat all types of patients, even immuno-depressed patients. Based
on the very positive Phase 2a clinical results, the Phase 2b/3
study between the United States and Europe aims to confirm a
significant reduction in mortality.
ABIONYX Pharma is the world leader in recombinant apoA-I, the
result of 20 years of expertise and innovation in lipid metabolism,
bioproduction and the clinical development of this unique
bioproduct. With its exceptional know-how, ABIONYX Pharma
demonstrated the safety, efficacy and therapeutic potential of
apoA-I in critical indications, particularly in LCAT deficiency, a
rare disease, and is now exploring the most severe inflammatory
diseases such as cytokine storms and severe inflammation in
ophthalmology and neurology.
Access here the full press release
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250219591056/en/
Investor relations abionyx@newcap.eu
Abionyx Pharma (EU:ABNX)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Abionyx Pharma (EU:ABNX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
